Two-year data showed significant functional improvements in patients treated with delandistrogene moxeparvovec compared to controls, despite initial trial endpoint failure. The treated group exhibited ...

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S.

Please provide your email address to receive an email when new articles are posted on . Upadacitinib is an oral JAK inhibitor under investigation for the treatment of multiple dermatologic indications ...

Final Phase 2 data show casdozokitug with atezolizumab/bevacizumab achieves a 17.2% complete response rate in HCC patients. Coherus BioSciences, Inc. announced ...

INCA033989 shows potential in treating myelofibrosis, with significant spleen volume reduction, anemia response, and symptom improvement in phase 1 studies. The investigational therapy demonstrates ...